Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Bartlett NL, et al. Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20. Leuk Lymphoma. 2017. PMID: 27868471 Clinical Trial.
Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV, Bartlett NL. Foyil KV, et al. Among authors: bartlett nl. Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Curr Hematol Malig Rep. 2010. PMID: 20446121 Review.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. Among authors: bartlett nl. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Free article. Clinical Trial.
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group. Furman RR, et al. Among authors: bartlett nl. Leuk Lymphoma. 2011 Apr;52(4):587-96. doi: 10.3109/10428194.2010.543714. Epub 2011 Jan 28. Leuk Lymphoma. 2011. PMID: 21275630 Free PMC article. Clinical Trial.
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Horwitz SM, et al. Among authors: bartlett nl. Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6. Blood. 2012. PMID: 22394596 Free article. Clinical Trial.
281 results